Moderna’s COVID-19 vaccine, mRNA-1273, demonstrated 93% efficacy through 6 months after administration of the second dose.
The efficacy data was based on a final analysis of the phase 3 COVE study (ClinicalTrials.gov Identifier: NCT04470427) which evaluated the efficacy and safety of the mRNA-1273 vaccine in more than 30,000 adults aged 18 years and older. The analysis showed that the vaccine “remains durable” through 6 months relative to its initial efficacy of 94.1% reported in November 2020.
Additionally, the Company is evaluating 3 different mRNA booster candidates in a phase 2 study, which included mRNA-1273, investigational mRNA-1273.351, and investigational mRNA-1273.211. Vaccination with 50mcg of the booster candidates have shown to elicit robust antibody responses against the wildtype D614G COVID-19 strain and against variants of concern including Gamma (P.1); Beta (B.1.351); and Delta (B.1.617.2). The data have been submitted to a peer-reviewed journal for publication.
“We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant,” said Stéphane Bancel, CEO of Moderna.
The Company has also filed for an Emergency Use Authorization (EUA) for the mRNA-1273 vaccine in adolescents aged 12 to 17 years based on data from its phase 2/3 TeenCOVE study (ClinicalTrials.gov Identifier: NCT04649151).
Moreover, the vaccine is being evaluated in an ongoing phase 2 KidCOVE study (ClinicalTrials.gov Identifier: NCT04796896) in patients 6 months to 11 years of age and in an ongoing phase 3 COVE Transplant study (ClinicalTrials.gov Identifier: NCT04860297) in adults with a kidney or liver transplant.
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates. News release. Moderna, Inc. Accessed August 6, 2021. https://investors.modernatx.com/news-releases/news-release-details/moderna-reports-second-quarter-fiscal-year-2021-financial.